CD4 and neoplasm: Despite a paucity of CD4<sup>+</sup> T cell receptor (TCR) clinical studies, CD4<sup>+</sup> T cells are primed to become important therapeutics as they help circumvent tumor antigen escape and guide multifactorial immune responses.